Hemerion
Lille, FR · 2 known investors
Find your way into Hemerion
67 people in our graph share verified history with the Hemerion team — schools, employers, funds. One of them is your warm intro.
Alain Rodermannunlockedknows Maximilien Vermandel · together at University of Lille 1 Sciences and Technology (overlapped)
×4knows the team · via University of Lille 1 Sciences and Technology
×6knows the team · via INSTITUT CURIE - HOPITAL RENÉ HUGUENIN
knows the team · via Université Paul Sabatier Toulouse III
Hemerion develops photonic drug-device combination therapies for treating glioblastomas and other brain tumors in clinical settings. The company combines photosensitizing drugs with innovative photonic systems designed to integrate into surgical workflows and selectively destroy tumor cells.
Founders & leadership
MV
Maximilien VermandelinMaximilien Vermandel holds a Master's degree in Automatic and Signal Processing from the University of Lille and a Master's degree in Medical Physics from the University Paul Sabatier, with nearly two decades of academic and research experience in brain tumor treatment. He was an associate professor at the University Hospital of Lille, where he led a research group focused on photodynamic therapy in neurosurgery, and is now founding Hemerion to develop photonic drug-device therapies for glioblastoma.
Investors · 2
In the news
Frequently asked questions
- What does Hemerion do?
- Hemerion develops photonic drug-device combination therapies for treating glioblastomas and other brain tumors in clinical settings. The company combines photosensitizing drugs with innovative photonic systems designed to integrate into surgical workflows and selectively destroy tumor cells.
- Who founded Hemerion?
- Hemerion was founded by Maximilien Vermandel.
- Who are Hemerion's investors?
- Hemerion's investors include Capital Cell, Bpifrance.
- Where is Hemerion headquartered?
- Hemerion is headquartered in Lille, FR.